West Pharma Files 8-K for Financial Results and Disclosure

Ticker: WST · Form: 8-K · Filed: Feb 15, 2024 · CIK: 105770

Sentiment: neutral

Topics: earnings, financial-disclosure, 8-K, regulatory-filing

TL;DR

**West Pharma just dropped an 8-K for financial results and disclosure, expect details soon!**

AI Summary

WEST PHARMACEUTICAL SERVICES, INC. filed an 8-K on February 15, 2024, to report on its Results of Operations and Financial Condition. The filing also included a Regulation FD Disclosure and Financial Statements and Exhibits. This current report, dated February 15, 2024, indicates the company is providing updated financial information to the public.

Why It Matters

This 8-K filing provides investors with crucial updates on WEST PHARMACEUTICAL SERVICES, INC.'s financial performance and operational status, enabling informed investment decisions. It ensures transparency and compliance with SEC regulations regarding material non-public information.

Risk Assessment

Risk Level: medium — While an 8-K for financial results provides transparency, the actual results could be positive or negative, introducing market volatility.

Key Players & Entities

FAQ

What is the name of the company that filed this 8-K?

The company that filed this 8-K is WEST PHARMACEUTICAL SERVICES, INC.

What was the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was February 15, 2024.

Which specific items were reported in this 8-K filing?

This 8-K filing reported on 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and 'Financial Statements and Exhibits'.

What is the state of incorporation for WEST PHARMACEUTICAL SERVICES, INC.?

WEST PHARMACEUTICAL SERVICES, INC. is incorporated in Pennsylvania.

What is the Commission File Number for the registrant?

The Commission File Number for WEST PHARMACEUTICAL SERVICES, INC. is 1-8036.

Filing Stats: 660 words · 3 min read · ~2 pages · Grade level 9.4 · Accepted 2024-02-15 07:51:00

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 15, 2024, West Pharmaceutical Services, Inc. (the "Company") issued a press release announcing its fourth-quarter and full year 2023 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information set forth in "Item 2.02 Results of Operations and Financial Condition," including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company's presentation materials used during the call will be available through the Investors link at the Company's website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description 99.1 West Pharmaceutical Services, Inc. Press Release, dated February 15, 2024. 99.2 West Pharmaceutical Services, Inc. Presentation, dated February 15, 2024. 104 The cover page from the Company's Current Report on Form 8-K, dated February 15, 2024, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEST PHARMACEUTICAL SERVICES, INC. /s/ Bernard J. Birkett Bernard J. Birkett Senior Vice President, Chief Financial and Operations Officer February 15, 2024 3 EXHIBIT INDEX Exhibit No. Description 99.1 West Pharmaceutical Services, Inc. Press Release, dated February 15, 2024 . 99.2 West Pharmaceutical Services, Inc. Presentation, dated February 15, 2024 . 104 The cover page from the Company's Current Report on Form 8-K, dated February 15, 2024, formatted in Inline XBRL. 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing